Dehaier, Heyer enter into three-year strategic mutual cooperation agreement

Dehaier Medical Systems Ltd. (NASDAQ: DHRM) ("Dehaier"), an emerging leader in the development, assembly, marketing and sale of medical devices and homecare medical products in China, today announced that the Company has entered into a three-year strategic mutual cooperation agreement with HEYER Medical AG ("Heyer"), an internationally recognized, Germany-based company specializing in state-of-the-art inhalation and anesthesia equipment, oxygen concentrators, breathing therapy equipment and connecting equipment. Management of both parties participated in the signing ceremony at Dehaier's headquarters in Beijing on June 5, 2012.

According to the Agreement, Dehaier will continue to be one of the key distributors for Heyer's anesthesia machines and exclusive distributor of nebulizers in China. Heyer's anesthesia machines and inhalation equipment currently holds a large market share in China, and Dehaier believes that there are a number of significant growth opportunities for Heyer's products throughout the country.  As Heyer's distributor, Dehaier will continue leveraging its solid professional sales force and strong customer base to promote and market Heyer's products. In addition to distributing Heyer's products in China, Dehaier will also provide medical products and technical services for Heyer, delivering high quality, cost-effective products to the majority of countries that Heyer serves, predominantly in Asia, East Asia and Africa.

Dehaier's CEO, Mr. Ping Chen stated, "We continue to build long-lasting relationships with many of the industry's most renowned medical manufacturers. I met with Mr. Klaus Schickhaus, CEO of Heyer Medical in Beijing last year, and he also showed great interest in Dehaier's homecare market portfolio and is reviewing opportunities for potential joint cooperation. We are delighted to be working with Heyer and welcome this opportunity for Dehaier to strengthen our international market expansion, enhance our brand awareness, improve our R&D capability, and eventually realize substantial growth in revenue for the benefit of our shareholders."